Published in J Invest Dermatol on July 29, 2014
Targeting vascular and leukocyte communication in angiogenesis, inflammation and fibrosis. Nat Rev Drug Discov (2015) 1.14
Intracellular Cleavage of the Cx43 C-Terminal Domain by Matrix-Metalloproteases: A Novel Contributor to Inflammation? Mediators Inflamm (2015) 0.85
Connexin 43 Inhibition Sensitizes Chemoresistant Glioblastoma Cells to Temozolomide. Cancer Res (2015) 0.83
Connexin hemichannels influence genetically determined inflammatory and hyperproliferative skin diseases. Pharmacol Res (2015) 0.79
Inhibition of connexin 43 hemichannel-mediated ATP release attenuates early inflammation during the foreign body response. Tissue Eng Part A (2015) 0.78
Healing refractory venous ulcers: new treatments offer hope. J Invest Dermatol (2015) 0.78
Connexins and their channels in inflammation. Crit Rev Biochem Mol Biol (2016) 0.77
The action of mimetic peptides on connexins protects fibroblasts from the negative effects of ischemia reperfusion. Biol Open (2015) 0.76
Altered connexin 43 expression underlies age-dependent decrease of regulatory T cell suppressor function in nonobese diabetic mice. J Immunol (2015) 0.76
The Role of Connexins in Wound Healing and Repair: Novel Therapeutic Approaches. Front Physiol (2016) 0.76
The C-terminal domain of connexin43 modulates cartilage structure via chondrocyte phenotypic changes. Oncotarget (2016) 0.75
Connexin-Based Therapeutics and Tissue Engineering Approaches to the Amelioration of Chronic Pancreatitis and Type I Diabetes: Construction and Characterization of a Novel Prevascularized Bioartificial Pancreas. J Diabetes Res (2015) 0.75
Bridging the gap to therapeutic strategies based on connexin/pannexin biology. J Transl Med (2016) 0.75
Connexins, Pannexins, and Their Channels in Fibroproliferative Diseases. J Membr Biol (2016) 0.75
Intramolecular signaling in a cardiac connexin: Role of cytoplasmic domain dimerization. J Mol Cell Cardiol (2017) 0.75
Rapid healing of venous ulcers and lack of clinical rejection with an allogeneic cultured human skin equivalent. Human Skin Equivalent Investigators Group. Arch Dermatol (1998) 3.26
Zonula occludens-1 alters connexin43 gap junction size and organization by influencing channel accretion. Mol Biol Cell (2005) 2.62
A systematic review of compression treatment for venous leg ulcers. BMJ (1997) 2.61
Chronic venous disease. N Engl J Med (2006) 2.35
Compression for venous leg ulcers. Cochrane Database Syst Rev (2012) 2.33
Compression for venous leg ulcers. Cochrane Database Syst Rev (2009) 2.22
Graftskin, a human skin equivalent, is effective in the management of noninfected neuropathic diabetic foot ulcers: a prospective randomized multicenter clinical trial. Diabetes Care (2001) 1.97
Guidance for industry: chronic cutaneous ulcer and burn wounds-developing products for treatment. Wound Repair Regen (2001) 1.95
Chronic venous insufficiency. Circulation (2005) 1.88
Connexin 43 connexon to gap junction transition is regulated by zonula occludens-1. Mol Biol Cell (2011) 1.81
Connexins and their channels in cell growth and cell death. Cell Signal (2005) 1.70
Advanced wound care therapies for nonhealing diabetic, venous, and arterial ulcers: a systematic review. Ann Intern Med (2013) 1.62
Connexins 26, 30, and 43: differences among spontaneous, chronic, and accelerated human wound healing. J Invest Dermatol (2004) 1.61
Mutations in connexin genes and disease. Eur J Clin Invest (2010) 1.56
The accuracy of venous leg ulcer prognostic models in a wound care system. Wound Repair Regen (2004) 1.48
Targeting connexin43 expression accelerates the rate of wound repair. Curr Biol (2003) 1.48
Novel therapies for scar reduction and regenerative healing of skin wounds. Trends Biotechnol (2008) 1.38
A peptide mimetic of the connexin43 carboxyl terminus reduces gap junction remodeling and induced arrhythmia following ventricular injury. Circ Res (2011) 1.29
Platelet-derived growth factor BB for the treatment of chronic pressure ulcers. Lancet (1992) 1.25
Venous ulcer: epidemiology, physiopathology, diagnosis and treatment. Int J Dermatol (2005) 1.22
A gene signature of nonhealing venous ulcers: potential diagnostic markers. J Am Acad Dermatol (2008) 1.13
Connexin43 carboxyl-terminal peptides reduce scar progenitor and promote regenerative healing following skin wounding. Regen Med (2009) 1.09
Surrogate endpoints for the treatment of venous leg ulcers. J Invest Dermatol (2002) 1.09
A phase II study to evaluate recombinant platelet-derived growth factor-BB in the treatment of stage 3 and 4 pressure ulcers. Arch Surg (1994) 1.03
The perinexus: a new feature of Cx43 gap junction organization. Heart Rhythm (2011) 1.00
Clinical and cost efficacy of advanced wound care matrices for venous ulcers. J Manag Care Pharm (2012) 0.98
Cardiac to cancer: connecting connexins to clinical opportunity. FEBS Lett (2014) 0.96
CASK (LIN2) interacts with Cx43 in wounded skin and their coexpression affects cell migration. J Cell Sci (2012) 0.93
NorLeu3-A(1-7) stimulation of diabetic foot ulcer healing: results of a randomized, parallel-group, double-blind, placebo-controlled phase 2 clinical trial. Wound Repair Regen (2012) 0.93
Managing the patient with venous ulcers. Ann Intern Med (2003) 0.91
Targeting Cx43 and N-cadherin, which are abnormally upregulated in venous leg ulcers, influences migration, adhesion and activation of Rho GTPases. PLoS One (2012) 0.90
The unstoppable connexin43 carboxyl-terminus: new roles in gap junction organization and wound healing. Ann N Y Acad Sci (2006) 0.89
Catecholamine stress alters neutrophil trafficking and impairs wound healing by β2-adrenergic receptor-mediated upregulation of IL-6. J Invest Dermatol (2013) 0.88
Wound Healing Society (WHS) venous ulcer treatment guidelines: what's new in five years? Wound Repair Regen (2012) 0.84
A prospective, multicentre, randomised controlled study of human fibroblast-derived dermal substitute (Dermagraft) in patients with venous leg ulcers. Int Wound J (2013) 0.83
The G60S Cx43 mutant enhances keratinocyte proliferation and differentiation. Exp Dermatol (2012) 0.82
Accelerated healing of diabetic wounds by NorLeu(3)-angiotensin (1-7). Expert Opin Investig Drugs (2011) 0.82
A randomized, controlled, double-blind prospective trial with a Lipido-Colloid Technology-Nano-OligoSaccharide Factor wound dressing in the local management of venous leg ulcers. Wound Repair Regen (2012) 0.82
Flavonoids for treating venous leg ulcers. Cochrane Database Syst Rev (2013) 0.81
Cell motility in models of wounded human skin is improved by Gap27 despite raised glucose, insulin and IGFBP-5. Exp Cell Res (2012) 0.80
Bioengineered alternative tissues and hyperbaric oxygen in lower extremity wound healing. Clin Podiatr Med Surg (2007) 0.79